[ Inside the business ]

VRTX stock analysis

VRTX · Vertex Pharmaceuticals Inc

Pharmaceutical preparations. Growing 12%. Keeps 33¢ of every dollar.

Watch: growth that has stopped speeding up.

The future, in 7 questions

Priced in: 4.1× sales in 5 yrs. Evidence: sales +12% · 33¢ profit/$1.

01 What's priced in?4.1× sales in 5 yrs
Sales now$13.0B
Needed in 5 yrs$52.7B
02 Is the wave rising?No Radar technology matched

Not among the companies mentioning Radar's technologies most.

03 Will customers keep buying?Sales +12%, steady
No customer over 10%
Prepaid $124MSales +12%, steady
04 Is it scarce?No
PricingBacklogPrepaidSell-outTight
05 More profit per sale?Keeps 33¢ per $1, falling
'21'22'23'24'2533¢
Before running costs: 88% → 86%
06 Can it fund itself?Pays its own way
05 yrsself-funded
Shares −0.5%/yrDebt $4.5B
07 What could break it?1 to watch
  • Growth peaked

From SEC filings, price and Radar. Not advice.

The record

Early signals

Growth peaked.

Sales growth +8%, +12%, then +12% vs. a year ago.

What could go wrong

Steadier than most.

It has moved 0.4× the market. In the 2018 q4 selloff it fell 14% while the market fell 14%. Debt is covered by cash.

Speculative check

Self-funding.

Passes every condition: profitable, cash-generating and financially sound.

What they sell

76% TRIKAFTA/KAFTRIO.

TRIKAFTA/KAFTRIO 76% · ALYFTREK 16% · Manufactured Product, Other 6% · CASGEVY 2%

Where each dollar goes

33¢ profit.

14¢ to make what it sells, 52¢ on research and overhead, 33¢ left over. Revenue $13.0B in the last 12 months.

Its market

1.5× the economy.

The government expects its industry, pharmaceutical and medicine manufacturing, to grow 3.0% a year to 2035, vs. 2.0% for the whole economy.

Market size and share

Your call.

There's no official size for its market. Enter one you trust to see its share, and slide to see what a bigger share would mean.

Life cycle

Growth.

It earns cash, invests heavily, and still raises money to grow.

Earnings quality

Some warning signs.

A few of its numbers drift toward the pattern of past manipulators. Cash covers 93¢ of each $1 of profit.

Competitive advantage

7 of 10 years.

Returns beat its 7.1% cost of capital in 7 of the last 10 years. Gross margin went from 88% to 86%.

Future bets

33% on research.

$4.2B a year on R&D. $492M on equipment and buildings.

All figures from Vertex Pharmaceuticals Inc's SEC filings (EDGAR) unless tagged otherwise. Educational only, not investment advice.